Gracell Reveals Encouraging Data From Pretreated Multiple Myeloma Patients

  • Gracell Biotechnologies Inc GRCL announced the updated clinical data on GC012F, an autologous CAR-T therapeutic candidate dual-targeting B-cell maturation antigen (BCMA) and CD19, for relapsed/refractory multiple myeloma (RRMM).
  • From October 2019 to January 2022, 29 heavily pretreated patients were enrolled and treated with a single infusion of GC012F at three dose levels (DL).
  • At the data cutoff of June 8, 2022, the response rate at different dose levels was 100% (2/2) in DL1, 80% (8/10) in DL2, and 100% (17/17) in DL3. 
  • All 29 patients achieved minimal residual disease (MRD) negativity. 75.9% of all patients treated achieved MRD-sCR. At the data cutoff, the median duration of response (DOR) was 15.7 months.
  • The safety profile of GC012F was consistent with previous findings with a primarily low grade of cytokine release syndrome (CRS).
  • Additionally, Gracell presented the first results of Phase 1 investigator-initiated study in China of GC012F in B-cell non-Hodgkin's lymphoma patients.
  • All three patients achieved a complete response (CR) confirmed at day 28 after GC012F infusion. 
  • At the 3-month follow-up, both assessable patients had an ongoing response. No dose-limiting toxicities and immune effector cell-associated neurotoxicity syndrome were observed. 
  • CRS presented as Grade 1 in two patients and Grade 3 in one patient with no Grade 4 or 5 events.
  • Price Action: GRCL shares are down 13.11% at $2.86 on the last check Monday.

Posted In: Briefswhy it's movingBiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.